CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
超越恶性肿瘤：CAR-T 细胞治疗自身免疫性疾病的临床进展
英文原题：Beyond malignancies: Clinical advancements of CAR T-cell in the treatment of autoimmune diseases.
查看英文原题
Beyond malignancies: Clinical advancements of CAR T-cell in the treatment of autoimmune diseases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向B细胞的嵌合抗原受体（CAR）T细胞疗法已成为血液系统恶性肿瘤治疗的突破，并在自身免疫性疾病中展现出良好潜力。在自身免疫病中，选择性靶向B细胞活化和自身抗体产生是一种创新治疗方法，但由于组织内B细胞清除不完全以及难以确定理想靶抗原，许多患者的临床应答仍不理想。过去4年间，自体或异基因CAR-T 细胞疗法在自身免疫性疾病中显示出显著疗效，可快速、持久地清除B细胞，并实现完全临床及血清学缓解。本综述考察B细胞靶向CAR-T 细胞疗法的当前格局、自身免疫性疾病中的治疗应用、正在开展的转化研究及未来发展。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has emerged as a breakthrough treatment for hematological malignancies and shows promising potential in autoimmune diseases. While selective targeting of B-cell activation and autoantibody production represents an innovative therapeutic approach in autoimmune conditions, clinical responses remain suboptimal in many patients due to incomplete B-cell depletion in tissues and limitations in identifying ideal target antigens.
Over the past four years, autologous or allogeneic CAR T-cell therapy has demonstrated remarkable efficacy in autoimmune diseases, achieving rapid and sustained B-cell depletion alongside complete clinical and serological remission. This review examines the current landscape of B cell-targeting CAR T-cell therapy, its therapeutic applications in autoimmune disorders, ongoing translational research, and future developments.
论文信息
- 作者
- Fang X、Wei R、Zhu W、Hu Y、Liang H
- 单位
- Department of Neurology, Beilun District People's Hospital (Beilun Branch, The First Affiliated Hospital, Zhejiang University School of Medicine), Ningbo, China.China
- 文献类型
- 综述
- 期刊
- Intractable & rare diseases research2026 May 31
- 原文标识
- PubMed 42221047 · DOI 10.5582/irdr.2025.01057
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →